Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Opioid Receptor Antagonist Market: Competitive Landscape, Pipeline, and Market Analysis 2024
Opioid Receptor Antagonist Market: Competitive Landscape, Pipeline, and Market Analysis 2024
Opioid receptors are a group of inhibitory G protein-coupled receptors with opioids as ligands. The endogenous opioids are dynorphins, enkephalins, endorphins, endomorphins and nociceptin. The opioid receptors are 40% identical to somatostatin receptors (SSTRs). Opioid receptors are distributed widely in the brain, spinal cord, peripheral neurons, and digestive tract. Four different opioid receptor systems, Mu (μ), Delta (δ), Kappa (κ), opioid receptor like-1 (ORL1), and the most commonly used opioids for pain management act on μ opioid receptor (MOR) systems. Mechanism of action (MOA) of the Opioid Receptor Antagonist is by competitive displacement of opioid molecules at receptors, as well as the blocking of opioid access to the receptor sites. The binding of opioid receptor antagonists does not activate the receptors or produce any opioid-like effects. Instead, they act as neutral antagonists, effectively preventing the activation of the receptors by agonists.
Opioid Receptor Antagonists are used in the treatment of pain management, opioid-related disorders, psychotic disorders, CNS disorders, constipation, mood disorder, neuralgia, arthritis, diabetes mellitus, spinal stenosis, fractures, migraine, etc. Increased prevalence of chronic pain disorders and changing lifestyles, rising aging population,etc, are the key drivers for the Opioid Receptor Antagonist market. For instance, according to the Centers for Disease Control and Prevention 2023, around there were an estimated 20.9% of U.S. adults (51.6 million persons) experienced chronic pain, and 6.9% (17.1 million persons) experienced high-impact chronic pain. The introduction of newer products by market players may look for opportunities that greatly impact comprehensive research and development in Opioid Receptor Antagonists. For instance, AbbVie’s Viberzi (Eluxadoline) was launched to treat irritable bowel syndrome with diarrhea. Moreover, numerous market participants are developing innovative compounds to address the difficulties in therapy. For instance, Innoviva’s TD-1211 for the indication of constipation is under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for Opioid Receptor Antagonist:
Drugs under the Pipeline for Opioid Receptor Antagonist:
Clinical Activity and Developments of Opioid Receptor Antagonist:
Up until July 2023, there will be about 34 companies with over 34 compounds that focus on various forms of pain and digestive disorders. For these molecules, more than 125 of clinical trials are being conducted and majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Embeda (Morphine & Sequestered Naltrexone) |
8 |
|
TD-1211 |
8 |
|
Moxduo IR (Morphine + Oxycodone) |
7 |
|
Bevenopran (CB-5945) |
7 |
|
Naltrexone Implant (OLANI) |
7 |
The molecules such as Brixadi (Buprenorphine) Extended Release Subcutaneous Injection developed by Braeburn for the line of treatment for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Alkermes’s Lybalvi (Olanzapine And Samidorphan) is used to treat Schizophrenia and Bipolar disorders in adults. Moreover, Adapt’s Narcan (Naloxone Hydrochloride) is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and central nervous system depression.
Total sales of Alkermes Lybalvi (Olanzapine And Samidorphan) for the entire year were US$96 million in FY2022 globally. Naloxone, naltrexone, and Nalgene are the most commonly used opioid antagonists across the globe. Opioid antagonist is considered an ideal medication to deal with the opioid medication crisis in most developed countries. It is a proven medication that saves the life of a patient addicted to opioids. The emergence of the opioid epidemic is one of the prominent factors driving the global opioid antagonists market. The opioid epidemic refers to the rise in the number of deaths and hospitalizations due to overdosage of opioids (including prescriptions, illicit drugs, and analogs). For instance, according to the National Institute on Drug Abuse in the US, around every day, around 128 people died due to overdosage of opioids in the country in 2018. Addiction to and misuse of opioids, including pain-reliever opioids, heroin, and synthetic opioids, leads to significant crises in social, economic, and public health. Opioids are commonly prescribed for underlying causes of chronic pain, such as cancer, trauma and injury cases, post-operative pain, and arthritis disorders.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Brixadi (Buprenorphine) ER Subcutaneous Injection, Lybalvi (Olanzapine And Samidorphan), Narcan (Naloxone Hydrochloride) are the FDA approved Opioid Receptor Antagonist.
Total sales of Alkermes Lybalvi (Olanzapine And Samidorphan) for the entire year were US$96 million in FY2022 globally.
Alkermes, Braeburn, Adapt, Pfizer are few leading market players in Opioid Receptor Antagonist Market.
Pain Management, Opioid Related Disorder, Psychotic Disorder, CNS Disorder, Constipation, Mood Disorder, Neuralgia, and Arthritis, are the major Indications of Opioid Receptor Antagonist
There are a total of 21 molecules that are in the Phase-1, Phase-2 and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.